Prescribing Information | GileadPro

This website is developed and funded by Gilead Sciences Ltd and intended for healthcare professionals in the United Kingdom. Adverse Event Reporting

Oncology Prescribing Information
Prescribing information for TRODELVY® ▼ (sacituzumab govitecan)

Gilead Sciences Ltd. is not responsible for third-party site content, except for information we have verified and provided.

Stay up to date

Receive email updates from Gilead, including promotional communications.

Register

April 2025 UKI-TRO-0277

Adverse events should be reported.

For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app (download from the Apple App Store or Google Play Store). For IE, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971. Adverse events should also be reported to Gilead to [email protected] or +44(0) 1223 897500 or +353(0) 21 482 5999.